Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA, Larkin J, Sznol M, Franke F, Ciuleanu TE, Pereira C, Muñoz Couselo E, Bronzon Damian F, Schenker M, Perfetti A, Lebbe C, Quéreux G, Meier F, Curti BD, Rojas C, Arriaga Y, Yang H, Zhou M, Ravimohan S, Statkevich P, Tagliaferri MA, Khushalani NI. Diab A, et al. Among authors: perfetti a. J Clin Oncol. 2023 Oct 20;41(30):4756-4767. doi: 10.1200/JCO.23.00172. Epub 2023 Aug 31. J Clin Oncol. 2023. PMID: 37651676 Free PMC article. Clinical Trial.
Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting.
Rizzo MM, Bluthgen MV, Recondo G, Naveira M, Perfetti A, Rizzi F, Kuzminin A, Faura V, Cerini M, Videla A, Silva C, Lupinacci L, Minatta N. Rizzo MM, et al. Among authors: perfetti a. Int J Clin Oncol. 2021 Jun;26(6):1057-1064. doi: 10.1007/s10147-021-01896-x. Epub 2021 Mar 14. Int J Clin Oncol. 2021. PMID: 33715058
Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).
Enrico D, Gomez JE, Aguirre D, Tissera NS, Tsou F, Pupareli C, Tanco DP, Waisberg F, Rodríguez A, Rizzo M, Minatta N, Rafael P, Basbus L, Lupinacci L, Kaen D, Ramos M, Bluthgen V, Castagneris N, Coppola MP, Scocimarro A, Guerra MF, Perfetti A, Levit P, Galvez-Nino M, Mas L, Rojas L, Zuluaga J, Chacón M, Corrales L, Samtani S, Arrieta O, Cardona A, Remon J, Martín C. Enrico D, et al. Among authors: perfetti a. Clin Lung Cancer. 2024 Dec;25(8):723-731.e2. doi: 10.1016/j.cllc.2024.09.005. Epub 2024 Sep 21. Clin Lung Cancer. 2024. PMID: 39424512
Third national surgical consensus conference of the Italian Association of Breast Surgeons (ANISC) on management after neoadjuvant chemotherapy: The difficulty in reaching a consensus.
Schiavone A, Ventimiglia F, Zarba Meli E, Taffurelli M, Caruso F, Gentilini OD, Del Mastro L, Livi L, Castellano I, Bernardi D, Minelli M, Fortunato L; ANISC Collaborative Group. Schiavone A, et al. Eur J Surg Oncol. 2024 Jul;50(7):108351. doi: 10.1016/j.ejso.2024.108351. Epub 2024 Apr 24. Eur J Surg Oncol. 2024. PMID: 38701582
Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G, Enrico D, Mahmoud YD, Ruiz A, Cantarella MF, Leguina L, Barberis M, Beña A, Brest E, Starapoli S, Mendoza Bertelli A, Tsou F, Pupareli C, Coppola MP, Scocimarro A, Sena S, Levit P, Perfetti A, Aman E, Girotti MR, Arrieta O, Martín C, Salanova R. Ruiz G, et al. Among authors: perfetti a. Thorac Cancer. 2024 Apr;15(11):895-905. doi: 10.1111/1759-7714.15244. Epub 2024 Mar 8. Thorac Cancer. 2024. PMID: 38456253 Free PMC article.
Time-controlled and muscle-specific CRISPR/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene.
Cardinali B, Provenzano C, Izzo M, Voellenkle C, Battistini J, Strimpakos G, Golini E, Mandillo S, Scavizzi F, Raspa M, Perfetti A, Baci D, Lazarevic D, Garcia-Manteiga JM, Gourdon G, Martelli F, Falcone G. Cardinali B, et al. Among authors: perfetti a. Mol Ther Nucleic Acids. 2021 Nov 29;27:184-199. doi: 10.1016/j.omtn.2021.11.024. eCollection 2022 Mar 8. Mol Ther Nucleic Acids. 2021. PMID: 34976437 Free PMC article.
Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1.
Voellenkle C, Perfetti A, Carrara M, Fuschi P, Renna LV, Longo M, Sain SB, Cardani R, Valaperta R, Silvestri G, Legnini I, Bozzoni I, Furling D, Gaetano C, Falcone G, Meola G, Martelli F. Voellenkle C, et al. Among authors: perfetti a. Int J Mol Sci. 2019 Apr 19;20(8):1938. doi: 10.3390/ijms20081938. Int J Mol Sci. 2019. PMID: 31010208 Free PMC article.
High-throughput analysis of the RNA-induced silencing complex in myotonic dystrophy type 1 patients identifies the dysregulation of miR-29c and its target ASB2.
Cappella M, Perfetti A, Cardinali B, Garcia-Manteiga JM, Carrara M, Provenzano C, Fuschi P, Cardani R, Renna LV, Meola G, Falcone G, Martelli F. Cappella M, et al. Among authors: perfetti a. Cell Death Dis. 2018 Jun 28;9(7):729. doi: 10.1038/s41419-018-0769-5. Cell Death Dis. 2018. PMID: 29955039 Free PMC article.
35 results